Pancreatic Cancer
Conditions
Brief summary
A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.
Detailed description
A study to collect survival status of CA046 subjects who were know to be alive at the last report of vital status for CA046 - approximate timeframe - end of March, 2013. Once consent is given, on a quarterly basis, information on status will be collected to include: * Vital Status * Date of disease progression * Subsequent anticancer therapy for pancreatic adenocarcinoma
Interventions
DRUGABI-007
No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
Sponsors
Celgene
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Must have been enrolled in the CA046 study Must have been living at the time of the last survival follow-up (approximate timeframe - end of March, 2013) Must understand and be able to give informed consent (if a subject is deceased, proper legal consent (ie, next of kin, legal representative) will be obtained prior to collection of data)
Exclusion criteria
* Consent refused for any reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | up to 3 years | Number of participants who survive |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease progression | up to 3 years | Date of disease progression and subsequent anticancer therapy for pancreatic adenocarcinoma other than that already recorded for subject while enrolled in CA046 |
Countries
Australia, Austria, Canada, France, Germany, Italy, Spain, Ukraine, United States
Outcome results
None listed